Atossa Genetics Inc（纳斯达克代码：ATOS）于4月13日与美国证券交易委员会提交文件，宣布公司已签署和解协议，正式了结围绕抗癌药物Endoxifen的专利争议。该协议标志着公司成功化解了潜在的知识产权风险，为Endoxifen的后续商业化进程扫清了法律障碍。
根据披露的条款，和解协议涉及双方就专利范围的重新界定及未来收益分配机制达成共识。Endoxifen作为Atossa Genetics研发管线中的核心产品，其专利纠纷的解决将显著提升投资者对药物上市前景的信心。此次和解不仅避免了冗长的诉讼程序，更体现出公司在知识产权战略管理上的成熟运作。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.